Ipsen data show CP spasticity undertreated

A presentation given by Basking Ridge, NJ-based Ipsen Biopharmaceuticals in September at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine in Montreal, Canada, found more than 40% of children with cerebral palsy (CP) receive none of 10 common therapies for the motor disorder. The retrospective study analyzed two years (2013-2015) of Medicaid data from a seven-million-person database, identifying 3294 unique cases of children with CP; 42% of these children didn’t receive any of 10 therapies identified by an expert panel as those most commonly used for spasticity management

A presentation given by Basking Ridge, NJ-based Ipsen Biopharmaceuticals in September at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine in Montreal, Canada, found more than 40% of children with cerebral palsy (CP) receive none of 10 common therapies for the motor disorder. The retrospective study analyzed two years (2013-2015) of Medicaid data from a seven-million-person database, identifying 3294 unique cases of children with CP; 42% of these children didn’t receive any of 10 therapies identified by an expert panel as those most commonly used for spasticity management

More:
Ipsen data show CP spasticity undertreated